Downloads: 469 | Views: 886 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Informative Article | Medical Science | India | Volume 9 Issue 5, May 2020 | Popularity: 6.5 / 10

Rate This Article!      

Review of the Available Treatment for COVID-19

Dr. Darshankumar Manubhai Raval, Dr. Vaishnavi Rathod, Dr. Dhwani Maheshwari, Dr. Poojan Thakkar, Dr. Tejas Gopalkrishnan, Dr. Tapan Patel

Abstract: In the late 2019, a novel corona virus appeared as outbreak of acute respiratory illness in wuhan, a city in china. Causative virus for the illness is known as SARS corona virus 2. the name given to the illness by WHO is COVID-19. (CORONA VIRUS DISEASE 2019). WHO designated it as public health emergency as it caused respiratory illness worldwide among multiple countries. It should be suspected in the patients with fever and/or respiratory track symptoms. It has a incubation period of 2-14 days (median 4-5days). It can cause mild pneumonia in about 80 % cases, severe infection in about 14 % cases. Among those 14 % cases, 5 % can develop critical illness like acute respiratory failure, shock, multiple organ dysfunction syndrome. Case fatality rate is variable among countries. It seems 2-3 % among most of countries. It presents as variable symptoms like fever (90 %), fatigue (70 %), dry cough (60 %), anorexia (40 %), productive cough (30 %), ARDS (20 %), headache, sorethroat, nausea, vomiting, muscle ache, diarrhea. Various treatments have been tried in multiple clinical trials but no drug has been aproved by FDA yet. FDA just released statement on compansionate use of hydroxychloroquin. Here we discuss multiple trials about use of drugs in COVID-19.

Keywords: COVID-19, Treatment, Trials, Coronavirus, Pandemic, hydroxychloroquine, SARS-CoV

Edition: Volume 9 Issue 5, May 2020

Pages: 308 - 318

Make Sure to Disable the Pop-Up Blocker of Web Browser

Click to Cite this Article

Similar Articles